The Shotlee Journal
Browse Shotlee articles about Weight Management.
Showing 9 / 872 Weight Management articles
The surge in GLP-1 weight-loss injections like semaglutide in India, fueled by prices dropping up to 90%, is alarming doctors amid rising cosmetic misuse by young women. Social media and wedding pressures are pushing unsupervised use, risking serious side effects. Experts stress these are prescription therapies for obesity, not quick fixes.
Looksmaxxing started in incel circles but mirrors women's long history of extreme beauty pursuits, from plastic surgery to Ozempic weight loss. Radical tactics like bone-smashing and crystal meth highlight its dangers, while celebrity denials fuel uncanny reactions. Unpack the cultural shift pushing men into fraught body modification.
The launch of generic Semaglutide in India has rapidly captured 33% market share within just 10 days, according to CLSA's channel checks, primarily benefiting Torrent Pharmaceuticals, Dr. Reddy's Laboratories, and Zydus Lifesciences. This surge has dented Eli Lilly's Mounjaro share from 61% to 56%. As generics make GLP-1 therapies more accessible, what does this mean for patients with type 2 diabetes and obesity?
Popular drugs like semaglutide and tirzepatide are transforming weight loss for type 2 diabetes and obesity patients. But a new UNC study warns of hidden muscle loss that could impact strength and mobility. Here's what the research means for safe, healthy weight management.
Health Canada recently warned Canadians not to buy or use unauthorized injectable peptide drugs amid reports of adverse reactions. Yet CBC News effortlessly purchased three such products online from different sellers. Experts highlight serious risks and contrast them with regulated GLP-1 medications like Ozempic and Wegovy.
Social media is spotlighting GLP-1 receptor agonist side effects that clinical trials overlooked, according to a new study in Nature Health. Researchers sifted through 410,198 Reddit posts on semaglutide and tirzepatide, finding 43.5% of users reporting issues like nausea and fatigue. These insights reveal patient concerns beyond traditional data.
While most people on GLP-1 medications like Wegovy experience significant weight loss, 10-15% are non-responders. Emerging research shows these drugs still improve liver health, reduce heart risks, and more—independent of weight changes. A new mouse study reveals why, challenging insurance requirements for weight loss thresholds.
Amazon and Walmart are racing to dominate GLP-1 medications like Eli Lilly's new oral Foundayo, but their strategies extend far beyond filling prescriptions for weight loss. With same-day delivery, telehealth, and integrated services, they're building 'continuous care commerce' platforms. This shift promises ongoing patient support for long-term therapy success.
A groundbreaking study reveals tirzepatide outperforms semaglutide and insulin degludec in speeding up blood sugar control and weight loss for type 2 diabetes patients. Participants on tirzepatide hit HbA1c targets below 7% in just eight weeks, compared to twelve weeks for alternatives. These faster results could boost long-term adherence and health outcomes.
